Novo Nordisk Jumps 24.9% in 30 Days as AI Drug Pipelines Win Market Confidence
Novo Nordisk posted a 24.9% stock surge over 30 days, backed by strong Q1 2026 earnings and a strategic pivot toward AI-augmented drug discovery. The company is licensing its Parkinson's program to Cellular Intelligence, an AI-native cell therapy developer, while refocusing capital on GLP-1. NVIDIA's BioNeMo platform is emerging as shared infrastructure across pharma, signaling a sector-wide shift from AI experimentation to AI deployment.
Salvado•